Study finds no added benefit of extensive ablation for persistent atrial fibrillation

In patients with persistent atrial fibrillation (AF), standard treatment with pulmonary vein isolation (PVI) ablation resulted in similar outcomes to more extensive ablation in other areas of the heart.

Most drugmakers have so far ignored looming FTC deadline to withdraw or amend wayward patents

With 10 days to go, only one company has responded to a demand by the U.S. Federal Trade Commission for several brand-name drugmakers to delist

December 6, 2023

Pharmalittle: We’re watching a ban of compounded versions of GLP-1s, a Biogen acquisition, and more

Good morning from San Diego. This is Jonathan Wosen, West Coast biotech and life sciences reporter, filling in for Ed Silverman while he’s away from

May 22, 2024

Artificial stone worktops pose serious health hazard

It may now be time to ban artificial stone-; a firm favorite for kitchen worktops in the UK-; to ward off the incurable lung disease

August 7, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.